A subscription to JoVE is required to view this content. Sign in or start your free trial.
* These authors contributed equally
This protocol provides reliable methods of solid tumor dissociation and myeloid cell isolation in murine intradermal or subcutaneous tumor models. Flow cytometry allows for phenotypic characterization of heterogeneous myeloid populations within the tumor microenvironment and sorting will demonstrate their functionality in the context of adoptive transfer.
The tumor-infiltrating myeloid cell compartment represents a heterogeneous population of broadly immunosuppressive cells that have been exploited by the tumor to support its growth. Their accumulation in tumor and secondary lymphoid tissue leads to the suppression of antitumor immune responses and is thus a target for therapeutic intervention. As it is known that the local cytokine milieu can dictate the functional programming of tumor-infiltrating myeloid cells, strategies have been devised to manipulate the tumor microenvironment (TME) to express a cytokine landscape more conducive to antitumor myeloid cell activity. To evaluate therapy-induced changes in tumor-infiltrating myeloid cells, this paper will outline the procedure to dissociate intradermal/subcutaneous tumor tissue from solid tumor-bearing mice in preparation for leukocyte recovery. Strategies for flow cytometric analysis will be provided to enable the identification of heterogeneous myeloid populations within isolated leukocytes and the characterization of unique myeloid phenotypes. Lastly, this paper will describe a means of purifying viable myeloid cells for functional assays and determining their therapeutic value in the context of adoptive transfer.
The tumor microenvironment (TME) is comprised of rapidly proliferating neoplastic cells and a surrounding heterogeneous stromal cell compartment. As growing tumors are often poorly vascularized, the TME is a peripheral site uniquely characterized by hypoxia, nutrient deprivation, and acidosis1. To survive in this landscape, tumor stress responses and metabolic reprogramming result in the secretion of soluble factors that promote tissue remodeling and angiogenesis as well as the selective recruitment of immune cells2. As myeloid cells are one of the most abundant type of hematopoietic cells in the TME, there is increasing....
NOTE: All animal studies complied with the Canadian Council on Animal Care guidelines and were approved by McMaster University's Animal Research Ethics Board.
1. Tumor harvest and dissociation
The results demonstrate that this method produces a high yield of myeloid cells from solid murine tumors. The preservation of receptor integrity and cellular viability facilitates reliable functional analysis of the desired myeloid subsets. These improvements to myeloid cell isolation allowed the discernment of the changing function of intratumoral myeloid cells upon normalization of the TME with the class I histone deacetylase inhibitor (HDACi), MS-275, during adoptive T cell therapy. TIL isolation protocols typically d.......
Although tumor-infiltrating myeloid cells exist in varying activation and differentiation states within the tumor, several subsets have been identified including tumor-associated DCs (TADCs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)12. Unfortunately, the overlapping expression of cell-surface markers used to identify these myeloid cell subsets makes it currently challenging to phenotypically differentiate tumor myeloid c.......
This work was supported by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario, as well as the Canadian Institutes of Health Research (FRN 123516 and FRN 152954), the Canadian Cancer Society (grant 705143), and the Terry Fox Research Institute (TFRI-1073).
....Name | Company | Catalog Number | Comments |
Alexa Fluor 700 Mouse Anti-Mouse CD45.2 | BD Biosciences | 560693 | 1:100 |
APC-Cy7 Mouse Anti-Mouse NK-1.1 | BD Biosciences | 560618 | 1:100 |
Biotin Mouse Anti-Mouse CD45.2 | BD Biosciences | 553771 | |
BV421 Hamster Anti-Mouse CD11c | BD Biosciences | 562782 | 1:100 |
BV650 Rat Anti-Mouse F4/80 | BD Biosciences | 743282 | 1:100 |
BV711 Rat Anti-Mouse CD8a | BD Biosciences | 563046 | 1:100 |
Collagenase, Type IV, powder | Gibco | 17104019 | |
DNase I | Roche | 10104159001 | |
EasySep Mouse CD11b Positive Selection Kit II | Stemcell technologies | 18970 | |
EasySep Mouse CD11c Positive Selection Kit II | Stemcell technologies | 18780 | |
EasySep Release Mouse Biotin Positive Selection Kit | Stemcell technologies | 17655 | |
FITC Rat Anti-Mouse Ly-6C | BD Biosciences | 553104 | 1:100 |
Fixable Viability Stain 510 | BD Biosciences | 564406 | 1:1000 |
Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm) | BD Biosciences | 554714 | |
PE Rat Anti-CD11b | BD Biosciences | 557397 | 1:100 |
PE-Cy7 Rat Anti-Mouse CD4 | BD Biosciences | 552775 | 1:100 |
PerCP-Cy5.5 Rat Anti-Mouse Ly-6G | BD Biosciences | 560602 | 1:100 |
Perm/Wash (BD Perm/Wash) | BD Biosciences | 554723 | |
Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block) | BD Biosciences | 553141 | |
iNOS Monoclonal Antibody (CXNFT), APC | Thermo Fisher | 17-5920-82 | 1:100 |
Human/Mouse Arginase 1/ARG1 Fluorescein-conjugated Antibody | R&D Systems | IC5868F | 1:100 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved